1
|
Derrick CJ, Szenker-Ravi E, Santos-Ledo A, Alqahtani A, Yusof A, Eley L, Coleman AHL, Tohari S, Ng AYJ, Venkatesh B, Alharby E, Mansard L, Bonnet-Dupeyron MN, Roux AF, Vaché C, Roume J, Bouvagnet P, Almontashiri NAM, Henderson DJ, Reversade B, Chaudhry B. Functional analysis of germline VANGL2 variants using rescue assays of vangl2 knockout zebrafish. Hum Mol Genet 2024; 33:150-169. [PMID: 37815931 PMCID: PMC10772043 DOI: 10.1093/hmg/ddad171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 09/11/2023] [Accepted: 09/28/2023] [Indexed: 10/12/2023] Open
Abstract
Developmental studies have shown that the evolutionarily conserved Wnt Planar Cell Polarity (PCP) pathway is essential for the development of a diverse range of tissues and organs including the brain, spinal cord, heart and sensory organs, as well as establishment of the left-right body axis. Germline mutations in the highly conserved PCP gene VANGL2 in humans have only been associated with central nervous system malformations, and functional testing to understand variant impact has not been performed. Here we report three new families with missense variants in VANGL2 associated with heterotaxy and congenital heart disease p.(Arg169His), non-syndromic hearing loss p.(Glu465Ala) and congenital heart disease with brain defects p.(Arg135Trp). To test the in vivo impact of these and previously described variants, we have established clinically-relevant assays using mRNA rescue of the vangl2 mutant zebrafish. We show that all variants disrupt Vangl2 function, although to different extents and depending on the developmental process. We also begin to identify that different VANGL2 missense variants may be haploinsufficient and discuss evidence in support of pathogenicity. Together, this study demonstrates that zebrafish present a suitable pipeline to investigate variants of unknown significance and suggests new avenues for investigation of the different developmental contexts of VANGL2 function that are clinically meaningful.
Collapse
Affiliation(s)
- Christopher J Derrick
- Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| | | | - Adrian Santos-Ledo
- Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| | - Ahlam Alqahtani
- Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| | - Amirah Yusof
- Genome Institute of Singapore (GIS), A*STAR, 60 Biopolis St, 138672, Singapore
| | - Lorraine Eley
- Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| | - Alistair H L Coleman
- Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| | - Sumanty Tohari
- Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis Dr, Proteos, 138673, Singapore
| | - Alvin Yu-Jin Ng
- Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis Dr, Proteos, 138673, Singapore
- MGI Tech Singapore Pte Ltd, 21 Biopolis Rd, 138567, Singapore
| | - Byrappa Venkatesh
- Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis Dr, Proteos, 138673, Singapore
| | - Essa Alharby
- Center for Genetics and Inherited Diseases, Taibah University, 7534 Abdul Muhsin Ibn Abdul Aziz, Al Ihn, Al-Madinah al-Munawwarah 42318, Saudi Arabia
- Faculty of Applied Medical Sciences, Taibah University, Janadah Bin Umayyah Road, Tayba, Al-Madinah al-Munawwarah 42353, Saudi Arabia
| | - Luke Mansard
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, 163 Rue Auguste Broussonnet, 34090 Montpellier, France
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, 80 Av. Augustin Fliche, 34000 Montpellier, France
| | | | - Anne-Francoise Roux
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, 163 Rue Auguste Broussonnet, 34090 Montpellier, France
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, 80 Av. Augustin Fliche, 34000 Montpellier, France
| | - Christel Vaché
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, 163 Rue Auguste Broussonnet, 34090 Montpellier, France
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, 80 Av. Augustin Fliche, 34000 Montpellier, France
| | - Joëlle Roume
- Département de Génétique, CHI Poissy, St Germain-en-Laye, 10 Rue du Champ Gaillard, 78300 Poissy, France
| | - Patrice Bouvagnet
- CPDPN, Hôpital MFME, CHU de Martinique, Fort de France, Fort-de-France 97261, Martinique, France
| | - Naif A M Almontashiri
- Center for Genetics and Inherited Diseases, Taibah University, 7534 Abdul Muhsin Ibn Abdul Aziz, Al Ihn, Al-Madinah al-Munawwarah 42318, Saudi Arabia
- Faculty of Applied Medical Sciences, Taibah University, Janadah Bin Umayyah Road, Tayba, Al-Madinah al-Munawwarah 42353, Saudi Arabia
| | - Deborah J Henderson
- Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| | - Bruno Reversade
- Genome Institute of Singapore (GIS), A*STAR, 60 Biopolis St, 138672, Singapore
- Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis Dr, Proteos, 138673, Singapore
- Smart-Health Initiative, BESE, KAUST, Thuwal, 23955-6900, Kingdom of Saudi Arabia
- Medical Genetics Department, Koç Hospital Davutpaşa Caddesi 34010 Topkapı Istanbul, Istanbul, Turkey
| | - Bill Chaudhry
- Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| |
Collapse
|
2
|
Vaché C, Cubedo N, Mansard L, Sarniguet J, Baux D, Faugère V, Baudoin C, Moclyn M, Touraine R, Lina-Granade G, Cossée M, Bergougnoux A, Kalatzis V, Rossel M, Roux AF. Identification and in vivo functional investigation of a HOMER2 nonstop variant causing hearing loss. Eur J Hum Genet 2023; 31:834-840. [PMID: 37173411 PMCID: PMC10326047 DOI: 10.1038/s41431-023-01374-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 04/18/2023] [Accepted: 04/25/2023] [Indexed: 05/15/2023] Open
Abstract
DFNA68 is a rare subtype of autosomal dominant nonsyndromic hearing impairment caused by heterozygous alterations in the HOMER2 gene. To date, only 5 pathogenic or likely pathogenic coding variants, including two missense substitutions (c.188 C > T and c.587 G > C), a single base pair duplication (c.840dupC) and two short deletions (c.592_597delACCACA and c.832_836delCCTCA) have been described in 5 families. In this study, we report a novel HOMER2 variation, identified by massively parallel sequencing, in a Sicilian family suffering from progressive dominant hearing loss over 3 generations. This novel alteration is a nonstop substitution (c.1064 A > G) that converts the translational termination codon (TAG) of the gene into a tryptophan codon (TGG) and is predicted to extend the HOMER2 protein by 10 amino acids. RNA analyses from the proband suggested that HOMER2 transcripts carrying the nonstop variant escaped the non-stop decay pathway. Finally, in vivo studies using a zebrafish animal model and behavioral tests clearly established the deleterious impact of this novel HOMER2 alteration on hearing function. This study identifies the fourth causal variation responsible for DFNA68 and describes a simple in vivo approach to assess the pathogenicity of candidate HOMER2 variants.
Collapse
Affiliation(s)
- Christel Vaché
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France.
- Institute for Neurosciences of Montpellier (INM), Univ Montpellier, Inserm, Montpellier, France.
| | - Nicolas Cubedo
- MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France
| | - Luke Mansard
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
| | | | - David Baux
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier (INM), Univ Montpellier, Inserm, Montpellier, France
| | - Valérie Faugère
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
| | - Corinne Baudoin
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
| | - Melody Moclyn
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
| | - Renaud Touraine
- Department of Genetics, CHU Hopital Nord, Saint-Etienne, France
| | - Geneviève Lina-Granade
- Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon University Hospital, Lyon, France
| | - Mireille Cossée
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
- PhyMedExp, Univ Montpellier, INSERM, CNRS, Montpellier, France
| | - Anne Bergougnoux
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
- PhyMedExp, Univ Montpellier, INSERM, CNRS, Montpellier, France
| | - Vasiliki Kalatzis
- Institute for Neurosciences of Montpellier (INM), Univ Montpellier, Inserm, Montpellier, France
| | | | - Anne-Françoise Roux
- Molecular Genetics Laboratory, Univ Montpellier, CHU Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier (INM), Univ Montpellier, Inserm, Montpellier, France
| |
Collapse
|
3
|
Nuzhat N, Van Schil K, Liakopoulos S, Bauwens M, Rey AD, Käseberg S, Jäger M, Willer JR, Winter J, Truong HM, Gruartmoner N, Van Heetvelde M, Wolf J, Merget R, Grasshoff-Derr S, Van Dorpe J, Hoorens A, Stöhr H, Mansard L, Roux AF, Langmann T, Dannhausen K, Rosenkranz D, Wissing KM, Van Lint M, Rossmann H, Häuser F, Nürnberg P, Thiele H, Zechner U, Pearring JN, De Baere E, Bolz HJ. CEP162 deficiency causes human retinal degeneration and reveals a dual role in ciliogenesis and neurogenesis. J Clin Invest 2023; 133:e161156. [PMID: 36862503 PMCID: PMC10104899 DOI: 10.1172/jci161156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 02/23/2023] [Indexed: 03/03/2023] Open
Abstract
Defects in primary or motile cilia result in a variety of human pathologies, and retinal degeneration is frequently associated with these so-called ciliopathies. We found that homozygosity for a truncating variant in CEP162, a centrosome and microtubule-associated protein required for transition zone assembly during ciliogenesis and neuronal differentiation in the retina, caused late-onset retinitis pigmentosa in 2 unrelated families. The mutant CEP162-E646R*5 protein was expressed and properly localized to the mitotic spindle, but it was missing from the basal body in primary and photoreceptor cilia. This impaired recruitment of transition zone components to the basal body and corresponded to complete loss of CEP162 function at the ciliary compartment, reflected by delayed formation of dysmorphic cilia. In contrast, shRNA knockdown of Cep162 in the developing mouse retina increased cell death, which was rescued by expression of CEP162-E646R*5, indicating that the mutant retains its role for retinal neurogenesis. Human retinal degeneration thus resulted from specific loss of the ciliary function of CEP162.
Collapse
Affiliation(s)
- Nafisa Nuzhat
- Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA
| | - Kristof Van Schil
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | - Sandra Liakopoulos
- Cologne Image Reading Center, Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany
- Department of Ophthalmology, Goethe University, Frankfurt, Germany
| | - Miriam Bauwens
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | - Alfredo Dueñas Rey
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | - Stephan Käseberg
- Institute of Human Genetics, University Medical Center Mainz, Mainz, Germany
| | - Melanie Jäger
- Department of Ophthalmology, Justus-Liebig-University Giessen, Giessen, Germany
- Augenarztpraxis Bad Brückenau, Bad Brückenau, Germany
| | | | - Jennifer Winter
- Institute of Human Genetics, University Medical Center Mainz, Mainz, Germany
| | - Hanh M. Truong
- Cell and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan, USA
| | - Nuria Gruartmoner
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | - Mattias Van Heetvelde
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | | | | | | | - Jo Van Dorpe
- Department of Diagnostic Sciences, Ghent University, Ghent, Belgium
- Department of Pathology, Ghent University Hospital, Ghent, Belgium
| | - Anne Hoorens
- Department of Diagnostic Sciences, Ghent University, Ghent, Belgium
- Department of Pathology, Ghent University Hospital, Ghent, Belgium
| | - Heidi Stöhr
- Institute of Human Genetics, University of Regensburg, Regensburg, Germany
| | - Luke Mansard
- Laboratoire de Génétique Moléculaire, CHU de Montpellier, Université de Montpellier, Montpellier, France
| | - Anne-Françoise Roux
- Laboratoire de Génétique Moléculaire, CHU de Montpellier, Université de Montpellier, Montpellier, France
| | - Thomas Langmann
- Laboratory for Experimental Immunology of the Eye, Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Katharina Dannhausen
- Laboratory for Experimental Immunology of the Eye, Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - David Rosenkranz
- Senckenberg Centre for Human Genetics, Frankfurt am Main, Germany
| | | | - Michel Van Lint
- Department of Ophthalmology, Brussels University Hospital, Jette, Belgium
| | - Heidi Rossmann
- Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany
| | - Friederike Häuser
- Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany
| | - Peter Nürnberg
- Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
| | - Holger Thiele
- Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Ulrich Zechner
- Institute of Human Genetics, University Medical Center Mainz, Mainz, Germany
- Senckenberg Centre for Human Genetics, Frankfurt am Main, Germany
| | - Jillian N. Pearring
- Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA
- Department of Ophthalmology and
- Cell and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan, USA
| | - Elfride De Baere
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | - Hanno J. Bolz
- Senckenberg Centre for Human Genetics, Frankfurt am Main, Germany
- Institute of Human Genetics, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
4
|
Mansard L, Baux D, Vaché C, Blanchet C, Meunier I, Willems M, Faugère V, Baudoin C, Moclyn M, Bianchi J, Dollfus H, Gilbert-Dussardier B, Dupin-Deguine D, Bonneau D, Drumare I, Odent S, Zanlonghi X, Claustres M, Koenig M, Kalatzis V, Roux AF. The Study of a 231 French Patient Cohort Significantly Extends the Mutational Spectrum of the Two Major Usher Genes MYO7A and USH2A. Int J Mol Sci 2021; 22:ijms222413294. [PMID: 34948090 PMCID: PMC8703989 DOI: 10.3390/ijms222413294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 12/03/2021] [Accepted: 12/08/2021] [Indexed: 01/06/2023] Open
Abstract
Usher syndrome is an autosomal recessive disorder characterized by congenital hearing loss combined with retinitis pigmentosa, and in some cases, vestibular areflexia. Three clinical subtypes are distinguished, and MYO7A and USH2A represent the two major causal genes involved in Usher type I, the most severe form, and type II, the most frequent form, respectively. Massively parallel sequencing was performed on a cohort of patients in the context of a molecular diagnosis to confirm clinical suspicion of Usher syndrome. We report here 231 pathogenic MYO7A and USH2A genotypes identified in 73 Usher type I and 158 Usher type II patients. Furthermore, we present the ACMG classification of the variants, which comprise all types. Among them, 68 have not been previously reported in the literature, including 12 missense and 16 splice variants. We also report a new deep intronic variant in USH2A. Despite the important number of molecular studies published on these two genes, we show that during the course of routine genetic diagnosis, undescribed variants continue to be identified at a high rate. This is particularly pertinent in the current era, where therapeutic strategies based on DNA or RNA technologies are being developed.
Collapse
Affiliation(s)
- Luke Mansard
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - David Baux
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
| | - Christel Vaché
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
| | - Catherine Blanchet
- National Reference Centre for Inherited Sensory Diseases, University Montpellier, CHU Montpellier, F-34000 Montpellier, France;
- Oto Laryngology Department, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France
| | - Isabelle Meunier
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
- National Reference Centre for Inherited Sensory Diseases, University Montpellier, CHU Montpellier, F-34000 Montpellier, France;
| | - Marjolaine Willems
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
- Medical Genetics Department, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France
| | - Valérie Faugère
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Corinne Baudoin
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Melody Moclyn
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Julie Bianchi
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Helene Dollfus
- Reference Center for Rare Affections in Ophthalmology Genetics (CARGO), Institute of Medical Genetics of Alsace, University of Strasbourg, CHU Strasbourg, F-67000 Strasbourg, France;
| | | | - Delphine Dupin-Deguine
- Medical Genetics Department, University of Toulouse, CHU Purpan, F-31000 Toulouse, France;
| | - Dominique Bonneau
- Medical Genetics Department, University of Angers, CHU Angers, F-49000 Angers, France;
| | - Isabelle Drumare
- Vision and Neuro-Ophthalmology Department, University of Lille, CHU Lille, F-59000 Lille, France;
| | - Sylvie Odent
- Clinical Genetics Service, University Hospital, Genetics and Development Institute of Rennes IDGDR, UMR6290 University of Rennes, F-35000 Rennes, France;
| | - Xavier Zanlonghi
- Center of Competence for Rare Diseases, Jules Verne Clinic, F-44000 Nantes, France;
| | - Mireille Claustres
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Michel Koenig
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
| | - Vasiliki Kalatzis
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
| | - Anne-Françoise Roux
- Molecular Genetics Laboratory, University of Montpellier, CHU Montpellier, F-34000 Montpellier, France; (L.M.); (D.B.); (C.V.); (V.F.); (C.B.); (M.M.); (J.B.); (M.C.); (M.K.)
- Institute for Neurosciences of Montpellier (INM), University of Montpellier, Inserm, F-34000 Montpellier, France; (I.M.); (M.W.); (V.K.)
- Correspondence:
| |
Collapse
|
5
|
Cenni C, Mansard L, Blanchet C, Baux D, Vaché C, Baudoin C, Moclyn M, Faugère V, Mondain M, Jeziorski E, Roux AF, Willems M. When Familial Hearing Loss Means Genetic Heterogeneity: A Model Case Report. Diagnostics (Basel) 2021; 11:diagnostics11091636. [PMID: 34573976 PMCID: PMC8465614 DOI: 10.3390/diagnostics11091636] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 09/04/2021] [Indexed: 11/29/2022] Open
Abstract
We describe a family with both hearing loss (HL) and thrombocytopenia, caused by pathogenic variants in three genes. The proband was a child with neonatal thrombocytopenia, childhood-onset HL, hyper-laxity and severe myopia. The child’s mother (and some of her relatives) presented with moderate thrombocytopenia and adulthood-onset HL. The child’s father (and some of his relatives) presented with adult-onset HL. An HL panel analysis, completed by whole exome sequencing, was performed in this complex family. We identified three pathogenic variants in three different genes: MYH9, MYO7A and ACTG1. The thrombocytopenia in the child and her mother is explained by the MYH9 variant. The post-lingual HL in the paternal branch is explained by the MYO7A variant, absent in the proband, while the congenital HL of the child is explained by a de novo ACTG1 variant. This family, in which HL segregates, illustrates that multiple genetic conditions coexist in individuals and make patient care more complex than expected.
Collapse
Affiliation(s)
- Camille Cenni
- Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CHU Montpellier, Université de Montpellier, 34090 Montpellier, France;
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
| | - Luke Mansard
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
| | - Catherine Blanchet
- Service ORL, CHU Montpellier, Université de Montpellier, 34090 Montpellier, France; (C.B.); (M.M.)
- Centre National de Référence Maladies Rares “Affections Sensorielles Génétiques”, CHU Montpellier, Université de Montpellier, 34090 Montpellier, France
| | - David Baux
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
- INM, Université de Montpellier, INSERM U1298, 34090 Montpellier, France
| | - Christel Vaché
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
- INM, Université de Montpellier, INSERM U1298, 34090 Montpellier, France
| | - Corinne Baudoin
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
| | - Mélodie Moclyn
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
| | - Valérie Faugère
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
| | - Michel Mondain
- Service ORL, CHU Montpellier, Université de Montpellier, 34090 Montpellier, France; (C.B.); (M.M.)
| | - Eric Jeziorski
- Service de Pédiatrie Générale, Infectiologie et Immunologie Clinique, CHU Montpellier, Université de Montpellier, 34090 Montpellier, France;
| | - Anne-Françoise Roux
- Laboratoire de Génétique Moléculaire, CHU Montpellier, Université de Montpellier, 34090 Monpellier, France; (L.M.); (D.B.); (C.V.); (C.B.); (M.M.); (V.F.); (A.-F.R.)
- INM, Université de Montpellier, INSERM U1298, 34090 Montpellier, France
| | - Marjolaine Willems
- Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CHU Montpellier, Université de Montpellier, 34090 Montpellier, France;
- Correspondence:
| |
Collapse
|
6
|
McNeill A, Iovino E, Mansard L, Vache C, Baux D, Bedoukian E, Cox H, Dean J, Goudie D, Kumar A, Newbury-Ecob R, Fallerini C, Renieri A, Lopergolo D, Mari F, Blanchet C, Willems M, Roux AF, Pippucci T, Delpire E. SLC12A2 variants cause a neurodevelopmental disorder or cochleovestibular defect. Brain 2020; 143:2380-2387. [PMID: 32658972 PMCID: PMC7447514 DOI: 10.1093/brain/awaa176] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Revised: 04/05/2020] [Accepted: 04/06/2020] [Indexed: 01/22/2023] Open
Abstract
The SLC12 gene family consists of SLC12A1-SLC12A9, encoding electroneutral cation-coupled chloride co-transporters. SCL12A2 has been shown to play a role in corticogenesis and therefore represents a strong candidate neurodevelopmental disorder gene. Through trio exome sequencing we identified de novo mutations in SLC12A2 in six children with neurodevelopmental disorders. All had developmental delay or intellectual disability ranging from mild to severe. Two had sensorineural deafness. We also identified SLC12A2 variants in three individuals with non-syndromic bilateral sensorineural hearing loss and vestibular areflexia. The SLC12A2 de novo mutation rate was demonstrated to be significantly elevated in the deciphering developmental disorders cohort. All tested variants were shown to reduce co-transporter function in Xenopus laevis oocytes. Analysis of SLC12A2 expression in foetal brain at 16-18 weeks post-conception revealed high expression in radial glial cells, compatible with a role in neurogenesis. Gene co-expression analysis in cells robustly expressing SLC12A2 at 16-18 weeks post-conception identified a transcriptomic programme associated with active neurogenesis. We identify SLC12A2 de novo mutations as the cause of a novel neurodevelopmental disorder and bilateral non-syndromic sensorineural hearing loss and provide further data supporting a role for this gene in human neurodevelopment.
Collapse
Affiliation(s)
- Alisdair McNeill
- Department of Neuroscience, University of Sheffield, Sheffield, UK,Neuroscience Institute, University of Sheffield, Western Bank, Sheffield, UK,Sheffield Clinical Genetics Service, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK,Correspondence to: Alisdair McNeill, PhD FRCP Edin DCH Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield, S10 2HQ, UK E-mail:
| | - Emanuela Iovino
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Luke Mansard
- Laboratory of Molecular Genetics, CHU Montpellier, University of Montpellier, Montpellier, France
| | - Christel Vache
- Laboratory of Molecular Genetics, CHU Montpellier, University of Montpellier, Montpellier, France
| | - David Baux
- Laboratory of Molecular Genetics, CHU Montpellier, University of Montpellier, Montpellier, France
| | - Emma Bedoukian
- Roberts Individualized Medical Genetics Center, Children’s Hospital of Philadelphia, Philadelphia, USA
| | - Helen Cox
- Regional Clinical Genetics Unit, Birmingham Women’s and Children’s Hospital NHS Foundation Trust, Mindelsohn Way, Birmingham, UK
| | - John Dean
- North of Scotland Genetics Service, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
| | - David Goudie
- East of Scotland Regional Genetics Service, Level 6, Ninewells Hospital, Dundee, UK
| | - Ajith Kumar
- Clinical Genetics Unit, Great Ormond Street Hospital, Great Ormond Street, London, UK
| | - Ruth Newbury-Ecob
- Bristol Regional Genetics Service, St Michael’s Hospital, Southwell Street, Bristol, UK
| | - Chiara Fallerini
- Medical Genetics, University of Siena, Siena, Italy,Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Alessandra Renieri
- Medical Genetics, University of Siena, Siena, Italy,Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Diego Lopergolo
- Medical Genetics, University of Siena, Siena, Italy,Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Francesca Mari
- Medical Genetics, University of Siena, Siena, Italy,Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Catherine Blanchet
- Centre of Reference for Genetic Sensory diseases, CHU Montpellier, University of Montpellier, Montpellier, France
| | - Marjolaine Willems
- Department of Clinical Genetics, CHU Montpellier, University of Montpellier, Montpellier, France
| | - Anne-Francoise Roux
- Laboratory of Molecular Genetics, CHU Montpellier, University of Montpellier, Montpellier, France
| | - Tommaso Pippucci
- Medical Genetics Unit, Polyclinic Sant’Orsola-Malpighi University Hospital, Bologna, Italy
| | - Eric Delpire
- Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, TN, USA,Correspondence to: Alisdair McNeill, PhD FRCP Edin DCH Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield, S10 2HQ, UK E-mail:
| |
Collapse
|